Cargando…
Should we use angiotensin II infusion in COVID-19-associated vasoplegic shock?
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7347253/ https://www.ncbi.nlm.nih.gov/pubmed/32646518 http://dx.doi.org/10.1186/s13054-020-03144-6 |
| _version_ | 1783556558193426432 |
|---|---|
| author | Bendjelid, Karim |
| author_facet | Bendjelid, Karim |
| author_sort | Bendjelid, Karim |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7347253 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-73472532020-07-10 Should we use angiotensin II infusion in COVID-19-associated vasoplegic shock? Bendjelid, Karim Crit Care Letter BioMed Central 2020-07-09 /pmc/articles/PMC7347253/ /pubmed/32646518 http://dx.doi.org/10.1186/s13054-020-03144-6 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| spellingShingle | Letter Bendjelid, Karim Should we use angiotensin II infusion in COVID-19-associated vasoplegic shock? |
| title | Should we use angiotensin II infusion in COVID-19-associated vasoplegic shock? |
| title_full | Should we use angiotensin II infusion in COVID-19-associated vasoplegic shock? |
| title_fullStr | Should we use angiotensin II infusion in COVID-19-associated vasoplegic shock? |
| title_full_unstemmed | Should we use angiotensin II infusion in COVID-19-associated vasoplegic shock? |
| title_short | Should we use angiotensin II infusion in COVID-19-associated vasoplegic shock? |
| title_sort | should we use angiotensin ii infusion in covid-19-associated vasoplegic shock? |
| topic | Letter |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7347253/ https://www.ncbi.nlm.nih.gov/pubmed/32646518 http://dx.doi.org/10.1186/s13054-020-03144-6 |
| work_keys_str_mv | AT bendjelidkarim shouldweuseangiotensiniiinfusionincovid19associatedvasoplegicshock |